Holen Sie sich die Stockscreener-App
258.75
0.58%
-1.52
Handel nachbörslich:
258.75
Insulet Corporation Aktie (PODD) Neueste Nachrichten
3 Reasons Investors Love Insulet (PODD) - Yahoo Finance
Insulet director Frederick Wayne sells $501,875 in stock By Investing.com - Investing.com Canada
Insulet director Frederick Wayne sells $501,875 in stock - Investing.com
Insulet glows with RADIANT results, CGMs becoming T2D standard - BioWorld Online
Insulet Gains 62.9% in a Year: What's Driving the Stock? - Yahoo Finance
Insulet (NasdaqGS:PODD) Completes US$450 Million Debt Financing; 7 Day Share Price Up 5% - Yahoo Finance
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today - Benzinga
Insulet Corp issues $450 million in senior notes By Investing.com - Investing.com Canada
Insulet Corp (PODD)'s Winning Formula: Financial Metrics and Com - GuruFocus.com
PODD Stock Gains Following the Launch of Omnipod 5 in Australia - Yahoo Finance
Insulet Corp issues $450 million in senior notes - Investing.com India
Insulet Closes $450 Million Senior Notes Issuance - TipRanks
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers - Yahoo Finance
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5 - Yahoo Finance
LendingTree and AMC Networks have been highlighted as Zacks Bull and Bear of the Day - TradingView
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections - BioSpace
Insulet's RADIANT Trial Results Highlight Significant Glycemic Benefits From Omnipod 5 Transition - Nasdaq
Omnipod 5 improves diabetes control in clinical trial By Investing.com - Investing.com South Africa
Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections - Lelezard
Insulet says data shows significant glycemic improvement with Omnipod 5 - Seeking Alpha
Insulet Reports Glycemic Improvements With Omnipod Automated Insulin Delivery System - Marketscreener.com
Insulet’s RADIANT trial demonstrates ‘meaningful’ glycemic improvements - TipRanks
Omnipod 5 improves diabetes control in clinical trial - Investing.com
5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections - Business Wire
From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes - Business Wire
3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan - TradingView
Insulet prices $450 million in senior notes due 2033 By Investing.com - Investing.com South Africa
Insulet announces proposed financing transactions - MSN
Insulet plans $450 million senior notes offering By Investing.com - Investing.com Australia
Insulet’s corporate family rating upgraded by Moody’s Ratings - Investing.com Canada
Insulet Announces Pricing of $450 Million Senior Notes - TipRanks
Insulet prices $450 million in senior notes due 2033 - Investing.com India
Insulet Announces Pricing of Senior Notes Due 2033 - Business Wire
Insulet Chief Technology Officer Mark Field leaves - MedTech Dive
Insulet Announces Proposed Financing Transactions - citybiz
Insulet Corporation (PODD): Among the Best Diabetes Stocks to Buy According to Billionaires - Insider Monkey
Insulet Corp. gets credit rating upgrade by S&P on strong performance and expected deleveraging - Investing.com South Africa
Insulet expands Omnipod 5 to more countries, prices $450M offering - Mass Device
Insulet Expands Omnipod® 5 to Four More International Markets - 01Net
Insulet Announces $450 Mln Offering Of Senior Unsecured Notes Due 2033 - Nasdaq
Insulet plans $450 million senior notes offering - Investing.com India
Insulet Announces $450M Senior Notes Offering - TipRanks
0.55%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):